Eventide Asset Management, LLC Cardiff Oncology, Inc. Transaction History

Eventide Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $1.72 Million - $3.83 Million	-1,467,922 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$2.11 - $7.25 $427,226 - $1.47 Million	-202,477 Reduced 12.12%	1,467,922 $3.64 Million
Q3 2021 Nov 15, 2021	SELL	$5.01 - $7.58 $9.55 Million - $14.4 Million	-1,905,435 Reduced 53.29%	1,670,399 $11.1 Million
Q2 2021 Aug 16, 2021	BUY	$6.65 - $10.04 $11.9 Million - $18 Million	1,792,346 Added 100.5%	3,575,834 $23.8 Million
Q1 2021 May 14, 2021	BUY	$9.1 - $19.57 $16.2 Million - $34.9 Million	1,783,488 New	1,783,488 $16.5 Million

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $170M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Eventide Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Eventide Asset Management, LLC with notifications on news.